Dec 19, 2019 / 11:00AM GMT
Operator
Hello, everyone, and welcome to today's conference call. (Operator Instructions)
Today, I am pleased to present CEO, Mattias Perjos; and CFO, Lars Sandström. Please go ahead.
Mattias Perjos - Getinge AB - CEO, President & Director
Thank you very much, and welcome to today's call. We would like to go through the background and rationale for the acquisition that we have announced today. So we can move directly to Slide #2, please.
So the headline here is that Getinge has signed an agreement to acquire Applikon Biotechnology, and the rationale for this in essence is that we would like to strengthen the offer to our biopharma customers. As you already know, we are already a world leader in solutions to prevent contamination in pharmaceutical production and to ensure integrity of research results. And with the acquisition of Applikon Biotechnology, we are acquiring a leading company in advanced bioreactor systems for bioprocessing and cell and gene therapy. The company has about SEK 450 million in revenue, and this is entirely towards the
Getinge AB to Acquire Applikon Biotechnology B.V. Call Transcript
Dec 19, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers